A recent study suggested that it can disrupt N-glycosylation by inhibiting the EMT/β-catenin/STT3/PD-L1 axis, leading to the downregulation of PD-L1 and the sensitization of cancer cells to anti-Tim-3 therapy by altering PD-L1 N-linked glycosylation [65]. Here, CD274 is linked to cancer.